NewsRx

Search our medical news database

Cancer Gene Therapy (Vectors)

Defective Herpes Simplex Viral Vector Successfully Transfers p53

Published in Cancer Weekly, October 9th, 1995

The first ever reported use of a defective herpes simplex virus (HSV) as a vector for transferring the gene for wild-type p53 (wt-p53) demonstrated in vitro success in a human medulloblastoma cell line.

Countless research efforts have shown that mutations of the p53 tumor-suppressor gene in human cancers play a critical role in carcinogenesis and tumor suppression. In keeping with technological advancements, restoring normal p53 function with wt-p53 in neoplasms with several different gene therapy techniques has shown varying levels of success [(T.J. Liu et al., Cancer Research, July 15, 1995;55(14):3117-3122) and (Y.L. Hou et al., at the 1995 8th International...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook